本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-017 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于 2025 年第一季度可转换公司债券转股情况的公告 特别提示： 1、九典转02转股期限为2024年3月21日至2029年9月14日，最新转股价格为 15.33元/股。 2、2025年第一季度，共有383张九典转02完成转股，对应票面金额为38,300 元，转股数量为2,495股。 3、截至2025年第一季度末，九典转02剩余2,053,514张，对应票面金额为 205,351,400元。 根据《深圳证券交易所创业板股票上市规则》有关规定，湖南九典制药股份 有限公司（以下简称"公司"）现将2025年第一季度可转换公司债券（以下简称 "可转债"）转股及公司股份变动情况公告如下： 一、可转换公司债券基本情况 转股期限自 2024 年 3 月 21 日起至 2029 年 9 月 14 日止。 二、可转债转 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-016 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于股东减持股份的预披露公告 股东熊英保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有本公司股份 720,929 股（占本公司总股本比例 0.145%）的财务总监熊 英女士，计划在本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式减 持本公司股份不超过 180,232 股（占本公司总股本比例 0.036%）。 公司于近日收到熊英女士出具的《股份减持计划告知函》。现将相关情况公 告如下： 二、本次减持计划的主要内容 | 股东名称 | 减持原因 | 股份来源 | 减持数量及比例 | 减持方式 | 减持期间 | 减持价格 | | --- | --- | --- | --- | --- | --- | --- | | 熊英 | 个人资金 | 公司首次公开 发行前已发行 的股份 ...

Group 1: Company Overview and Market Position - The company, Hunan Jiudian Pharmaceutical Co., Ltd., focuses on the production of external anti-inflammatory and analgesic products, specifically Loxoprofen and Ketoprofen gel patches, which are considered complementary in the market [2][3]. - The external patch market in 2023 has a sales scale of approximately ¥20.364 billion, with hospitals accounting for 69.89% and retail for 30.11% [4]. Group 2: Cost Control and Operational Efficiency - The company implements various measures for cost reduction, including self-production of raw materials and key auxiliary materials to ensure product quality while controlling costs [3]. - Continued efforts will be made to expand outpatient markets and optimize marketing models to further reduce sales expenses [5]. Group 3: Strategic Planning and Growth Potential - The company’s 2025 strategic plan focuses on three key areas: expanding sales channels, enhancing R&D for new product development, and optimizing production processes for efficient operations [7]. - There is significant growth potential for Loxoprofen sodium gel patches in the outpatient market, driven by stable demand and increasing consumer preference for convenient medication [8].

Core Viewpoint - Jiutian Pharmaceutical is actively responding to competitive product approvals by leveraging its complete industrial chain to control costs and ensure product quality while expanding its market presence through a robust sales strategy and continuous investment in R&D [2][4]. Group 1: Company Response to Competition - The company plans to actively respond to competitive product approvals by utilizing its complete industrial chain for self-production of raw materials and key auxiliary materials, ensuring product quality while effectively controlling costs [2]. - Jiutian Pharmaceutical has established a comprehensive sales coverage system, particularly in the outpatient market, which has become a new engine for revenue growth [2]. Group 2: Product Development and Market Strategy - The company is focusing on enhancing its "Jiuyue" brand of transdermal patches, aiming to deepen its influence in the transdermal drug delivery field through first-mover advantages, channel advantages, and cost advantages [2]. - The company is actively expanding its outpatient market presence and has planned a new sales strategy to increase resource investment in this area [4]. Group 3: Product Approval and Market Engagement - As of now, the procurement documents for the Lososofen Sodium Gel Patch in the Guangdong Alliance collection are still in the reporting stage, with no formal release yet [3]. - The company expects the approval of the Fluorobufen Gel Patch by the end of this year [7]. Group 4: Financial Performance - Jiutian Pharmaceutical reported a main revenue of 2.146 billion yuan for the first three quarters of 2024, a year-on-year increase of 13.36%, with a net profit attributable to shareholders of 450 million yuan, up 45.08% year-on-year [9]. - The company’s third-quarter revenue reached 780 million yuan, reflecting a 15.47% year-on-year increase, with a net profit of 166 million yuan, up 47.38% year-on-year [10]. Group 5: Share Buyback Progress - The company conducted its first share buyback on March 13, 2025, through centralized bidding, with further details available in its recent announcement [8].

Group 1: Company Strategy and Market Position - The company plans to actively respond to the impact of competitor product approvals by leveraging its complete industrial chain to control costs and ensure product quality [2] - A full-channel coverage system has been established, particularly in the outpatient market, which has become a new growth engine for performance [2] - Continuous high investment in R&D is maintained to innovate and expand the product line, with a focus on strengthening the "JiuYue" brand in the transdermal drug delivery sector [2] Group 2: Product Development and Market Expansion - The company is currently in the reporting phase for the procurement of the Loxoprofen Sodium Gel Patch in the Guangdong Alliance, with procurement documents not yet officially released [3] - Plans to enhance sales strategies for the Loxoprofen Sodium Gel Patch include increasing resource allocation to the outpatient market to boost market influence [4] - As of December 31, 2024, over 2,000 hospitals have been developed for the Ketoprofen Gel Patch, including more than 1,000 tier 2 and tier 3 hospitals [5] Group 3: Consumer Demographics and Product Approval - The primary consumer demographics for the Loxoprofen Sodium Gel Patch in retail pharmacies include patients with osteoarthritis, muscle pain, injuries, elderly individuals, laborers, and athletes [6] - The company anticipates that the Fluorobiprofen Gel Patch will be approved by the end of this year [7] Group 4: Share Buyback Progress - The company conducted its first share buyback on March 13, 2025, through centralized bidding, with details available in the recent announcement on the Giant Tide Information Network [8]

Market Overview - The transdermal patch industry is experiencing rapid growth due to factors such as an aging population facing chronic pain issues like arthritis and muscle pain, which increases market demand for patch products [2][3] - Public awareness of scientific medication and health management is rising, leading to a preference for convenient and safe external medications like transdermal patches [2][3] Company Advantages - The company benefits from a complete industrial chain, allowing for in-house production of active pharmaceutical ingredients and key excipients, ensuring product quality while controlling costs [3][8] - A comprehensive sales channel system has been established, particularly in the outpatient market, which is a new growth engine for performance [3] - Continuous high investment in R&D enables the company to innovate and expand its product line, enhancing its competitive edge [3][8] Product Strategy - The company is optimistic about the market prospects for its anti-inflammatory and analgesic patches, focusing on OTC channels and leveraging shared sales resources to boost sales [4] - The sales team consists of over 400 personnel, enhancing the company's market reach [5] Marketing and Promotion - Multi-channel collaboration strategies are employed for OTC promotion, integrating online and offline channels, including partnerships with pharmacies and e-commerce platforms [6][10] - The company emphasizes patient education and conducts health seminars to enhance consumer experience and trust [7] Future Directions - The company plans to focus on three key areas: expanding sales channels, particularly in outpatient markets, enhancing brand influence, and increasing R&D efforts for new product development [12][13] - Continuous optimization of production processes and cost control mechanisms will be prioritized to ensure efficient operations and good returns for shareholders [13] M&A Strategy - The company will consider various directions for mergers and acquisitions, focusing on targets that align with its strategic development, enhance market competitiveness, and enrich its product pipeline [11]

湖南九典制药股份有限公司 关于为全资子公司提供担保的进展公告 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-015 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 以上担保金额在公司已履行审议程序的担保额度以内，无需履行其他审议程 序。本次担保生效后，公司为九典宏阳提供担保的剩余总额度为人民币 27,700 万元整。 三、被担保人情况 公司名称：湖南九典宏阳制药有限公司 统一社会信用代码：91430122344723202P 类型：有限责任公司（自然人投资或控股的法人独资） 住所：湖南望城经济开发区铜官循环经济工业基地内 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南九典制药股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日、2024 年 5 月 15 日分别召开的第四届董事会第四次会议及 2023 年度股东大会审议通 过了《关于为全资子公司申请银行授信提供担保的议案》，同意公司为全资子公 司湖南九典宏阳制药有限公司（以下简称"九典宏 ...

湖南九典制药股份有限公司 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-013 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 关于首次回购公司股份的公告 公司首次回购股份的时间、回购股份数量、集中竞价交易的委托时间及交易 价格等均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》及 公司回购股份方案的相关规定。 公司后续将在回购期限内根据市场情况继续择机实施股份回购，并根据相关 法律法规及时履行信息披露义务，敬请投资者注意投资风险。 特此公告。 湖南九典制药股份有限公司董事会 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-014 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的相关情况 奥硝唑注射液由罗氏制药开发，1980 年瑞士首上市，随后在欧洲多国获批 上市，用于厌氧菌感染的术前预防和术后治疗以及肠道和肝脏严重的阿米巴病。 硝基咪唑类是预防和治疗厌氧菌感染的首选药物之一，其中奥硝唑是继甲硝唑、 替硝唑之后上市的第三代硝基咪唑类药物，与同类相比具有疗效确切、适用人群 更广、不良反应更小等优势，目前已在临床广泛用于普外科、妇产科、儿科等科 室，已被《抗菌药物临床应用指导原则（2015 年版）》和《胆道外科抗菌药物 规范化应用专家共识（2019 版）》等国内权威指南或专家共识推荐。根据米内 2、剂型：注射剂 3 ...

Group 1: Company Overview and Strategy - The company has a complete industrial chain layout, allowing for self-production of active pharmaceutical ingredients and key excipients, which helps control costs while ensuring product quality [2] - The company has established a comprehensive channel coverage system, particularly in the outpatient market, which has become a new growth engine for performance [2] - The company plans to continue increasing investment to capture a larger market share [2] Group 2: Product Development and Market Position - The company maintains high investment in R&D, continuously innovating and expanding its product line [2] - The "JiuYue" brand of transdermal patches is being developed to leverage first-mover, channel, and cost advantages, aiming to deepen its influence in the transdermal drug delivery field [2] - The company is optimistic about the market prospects for its anti-inflammatory and analgesic patch, anticipating a growing patient population due to aging society [3] Group 3: Sales and Marketing Strategies - The company utilizes social e-commerce platforms like Xiaohongshu, Douyin, and Kuaishou to promote health products and build private traffic [3] - The main sales channel for the anti-inflammatory and analgesic patch is the OTC channel, with strategies to enhance sales through resource sharing and product matrix expansion [3] Group 4: Product Portfolio and Research - The company has 8 products selected in the national centralized procurement, including various tablets and granules, contributing positively to growth [3] - There are many new oral solid dosage forms in the research pipeline, which are expected to support the company's stable development upon approval [3] Group 5: Workforce and M&A Strategy - The company currently employs over 400 sales personnel and over 400 R&D personnel [3] - In terms of mergers and acquisitions, the company considers targets that align with its strategic development, focusing on projects that enhance the industrial chain, technical capabilities, and market competitiveness [4]